On October 23, WUXI BIO fell 3.31% in Regular Trading, trading at HK$43.82, with turnover of HK$196 million.
The clearest catalyst behind the move was a recent UBS downgrade to Neutral, with a target price of RMB27, which pressured near-term risk appetite toward the stock.
Earlier disclosures had shown relatively solid operating trends, including interim revenue of RMB11.787 billion, adjusted net profit of RMB3.937 billion, and a rise in gross margin to 46.2%. The company had also announced that its Wuxi Mashan site passed an unannounced FDA GMP inspection with no critical or major findings. Even so, the latest rating change appears to have outweighed those positives in the current session, while other related names in the life sciences tools and services space also traded weaker.
The company provides end-to-end solutions for biologics discovery, development, and manufacturing, and also operates the XDC business focused on CRDMO services for ADCs and other bioconjugates.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments